touchLearning Activities
We are deeply saddened to learn that Prof. Marcus Maurer, a highly esteemed expert and valued member of the touchIMMUNOLOGY faculty, has been missing for several weeks following a hiking expedition in the mountains.
Managing hereditary angioedema effectively remains a significant challenge, but recent clinical trials presented at EAACI 2024, in Valencia, Spain, have shown promising advancements in treatment options.
The EASL 2024 meeting offered a great opportunity for hepatologists from around the world to discuss the latest data and tackle challenges in liver disease. Metabolic dysfunction-associated steatohepatitis (MASH) was a hot topic, with several exciting studies making waves. This article ...
As we have come to expect, EULAR 2024 was a busy and productive meeting, packed with news and lively discussions among rheumatologists. The conference, which took place in Vienna, Austria, highlighted a wealth of innovative research and significant advancements in rheumatology. ...
The European Alliance of Associations for Rheumatology (EULAR) proudly announces the launch of its 2024-2029 European Manifesto, addressing the urgent need for a coordinated response to rheumatic and musculoskeletal diseases (RMDs) across Europe.
Watch highlights of three ADVENT symposia presented at EADV 2023
Key updates from 2 cutting-edge expert symposia presented at WCD 2023
Triple-negative breast cancer (TNBC) is a breast cancer subtype that typically affects younger women, metastasizes early and carries a poor prognosis.1 However, it has a number of characteristics associated with enhanced response to immune checkpoint inhibitors, including increased tumour-infiltrating lymphocytes ...
The European Society of Medical Oncology (ESMO) Virtual Congress 2020 was held on 19–21 September 2020. Advances in immunotherapy featured prominently among the presentations and clinical trial updates. Below are some of the highlights of the late-stage clinical trial data that were presented. ...
Immunotherapy using agents targeting programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) is one of the biggest success stories of cancer treatment in recent decades; these immune checkpoint inhibitors can produce durable, long-term benefits without the toxicities associated with ...
touchIMMUNOLOGY
Register Now!
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
- Save your progress for video
- Keep track of your CME credits
- Add personalised learning notes
- Receive updates from course leaders and faculty
- Be the first to hear about new and exciting interactive learning opportunities
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
